Kronos Bio Strengthens Senior Management Team with New Leadership Appointments

Dr. Lee will play a critical role in establishing a Program Management function at Kronos across both its San Mateo and Cambridge offices. He will begin working at the company on November 4, 2019, in the San Mateo office. Dr. Lin will focus on the discovery of novel small molecules that modulate historically undruggable oncology targets. He will also develop Kronos’ bioinformatics capability, which will allow the company to fully leverage genomic and proteomic insights in the advancement of its discovery pipeline. Dr. Lin will begin his role at the company on December 20, 2019, in the Cambridge office.

“Chris and Charles have highly relevant track records in biopharma and academia, respectively, and their ability to help drive our pipeline strategy and platform will be invaluable as we grow,” said Norbert Bischofberger, Ph.D., President and Chief Executive Officer of Kronos. “Chris has nearly 20 years of research and project management experience from discovery through Phase 3 development and commercialization. Charles has been a rising star in academic medicine and has deep expertise in epigenetics and oncogenic transcription, which is ideally matched to our research focus on novel modulators or degraders of historically undruggable targets. His experience as a computational biologist will be essential in our discovery efforts against a range of validated, historically challenging oncology targets and in gleaning insights into underlying target biology.”

“I look forward to joining Kronos at this critical time in the company’s development as it continues to grow and mature its internal discovery pipeline,” said Dr. Lee. “Having spent my entire career involved in biopharmaceutical research and program management, I am excited to bring to Kronos my experience in drug research and clinical development strategy, team dynamics, risk mitigation and timeline acceleration.”

“After my time in academia, I decided to enter the biopharmaceutical industry because I wanted to make a more tangible impact on patient treatment. I am joining Kronos because of its impressive management team and Small Molecule Microarray platform, which has identified bioactive molecules against challenging oncology targets,” said Dr. Lin. “I look forward to leveraging my experience in altered gene control to help Kronos advance its promising pipeline of novel targets to address some of the most challenging diseases patients face today.”

Dr. Lee is joining Kronos from Gilead Sciences where he spent 19 years in roles of increasing responsibility. Most recently, he served as Senior Director, Research Portfolio Management, where he established a new Project Management department supporting research teams for projects in preclinical and clinical development across the company’s portfolio, including in oncology. Prior to becoming a project manager, Dr. Lee was a research scientist in the Medicinal Chemistry department. He earned a B.S. in chemistry from the University of California, Berkeley, a Ph.D. in organic chemistry from the University of California, Los Angeles, and an M.B.A. from Golden Gate University.

Dr. Lin is joining Kronos from Baylor College of Medicine, where he served as an Assistant Professor in the Department of Molecular and Human Genetics, a Pew-Stewart Scholar for Cancer Research, a CPRIT Scholar in Cancer Research, and was a scientific founder and Co-Director of the Therapeutic Innovation Center, an academic research center focused on accelerating therapeutic discovery against diseases of altered gene control. Dr. Lin was recruited to Baylor College of Medicine by the Cancer Prevention and Research Institute of Texas. In his interdisciplinary laboratory, Dr. Lin has investigated and targeted transcriptional deregulation in cancer. He received a B.S. in biology and physics from Duke University and a Ph.D. in computational and systems biology from the Massachusetts Institute of Technology. He completed a post-doctoral fellowship in the Department of Medical Oncology and Chemical Biology Program at the Dana-Farber Cancer Institute where he focused on targeting deregulation of transcription and chromatin regulators in cancer.

About Kronos Bio

Kronos Bio, Inc. is dedicated to the discovery and development of first-in-class therapies that modulate historically undruggable targets. Kronos’ small molecule microarray (SMM) platform enables high-throughput screens of chemical libraries against such targets in a physiologically relevant context to identify biologically active small molecules. SMM is ideally suited for rapid discovery of novel modulators or targeted degraders of historically undruggable targets, such as transcription factors and other central drivers of oncogenic signaling.

For more information, please visit www.kronosbio.com or follow the company on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191024005327/en/